Bill Ringo became a strategic advisor at Sofinnova Ventures in 2010. This was a natural transition for Bill and for Sofinnova, having shared a collaborative relationship through Bill's involvement in several of Sofinnova's portfolio companies. Bill has over 35 years of experience in the pharmaceutical and biotechnology industries.
Most recently, he was Senior Vice President of Strategy and Business Development for Pfizer. In 2001, he retired from Eli Lilly & Company after 28 years, with his most recent role being Product Group President for Oncology and Critical Care. During his tenure at Eli Lilly, Bill's positions included President of Internal Medicine Products, President of the Infectious Diseases business unit, and Vice President of Sales and Marketing for U.S. Pharmaceuticals.
Bill is the former President and CEO of Abgenix, which sold for $2.2 billion to Amgen in April 2006. Abgenix focused on developing human antibodies as agents to treat severe diseases such as cancer. Vectibix, developed to treat colorectal cancer, was Abgenix's first product launched by Amgen in 2006. From June 2003 to September 2003, Bill served as InterMune's interim President and CEO.
He holds a B.S. and an M.B.A. from the University of Dayton.